Insulet has named Flavia Pease as its new CFO, effective Sept. 30, the diabetes tech company announced Tuesday.
Pease, previously CFO of Charles River Laboratories, also worked at Johnson & Johnson for more than 20 years, including roles in both the company’s medical device and pharmaceutical segments. Pease worked as group CFO of J&J’s medical devices business, overseeing a $27 billion portfolio, and as vice president of finance for Janssen North America, J&J’s largest business unit.
New Insulet CEO Ashley McEvoy was also a longtime employee of J&J, leading the medtech business from 2018 to 2023. McEvoy said in a statement that Pease’s track record and leadership experience at global companies make her the ideal CFO to guide Insulet’s next phase of growth.
Pease has been a member of Insulet’s board since 2024, and she will resign from that role upon her appointment.
“We think Ms. Pease’s appointment will be well received given her extensive track record in healthcare and devices, and prior familiarity with Insulet,” J.P. Morgan analyst Robbie Marcus wrote in a Tuesday investor note.
Outgoing CFO Ana Maria Chadwick will become a senior adviser to the company to help with the transition. Chadwick has been CFO of Insulet since April 2024.
Insulet expects to exceed its forecast of 22% to 25% revenue growth for the third quarter, the company said in the announcement. Insulet’s next earnings call is scheduled for Nov. 6.
Dexcom CEO Kevin Sayer on leave
Outgoing Dexcom CEO Kevin Sayer is on a temporary medical leave of absence as of Sept. 14, the maker of glucose sensors said in a Monday securities filing.
Over the summer, Dexcom announced plans for Sayer to step down in January, with current Chief Operating Officer Jake Leach succeeding him as CEO.
While Sayer is on leave, Leach will serve as interim principal executive officer in addition to his work as COO. Mark Foletta, lead independent director of the board, will serve as interim chairman. They will not receive any additional compensation, the company said in the filing. Dexcom did not share any more details on when Sayer may return.
